Fazirsiran Injection
Sponsors
Takeda
Conditions
Alpha1-Antitrypsin Deficiency
Phase 3
Study to Check the Safety of Fazirsiran and Learn if Fazirsiran Can Help People With Liver Disease and Scarring (Fibrosis) Due to an Abnormal Version of Alpha-1 Antitrypsin Protein
RecruitingNCT05677971
Start: 2023-03-06End: 2031-12-12Target: 160Updated: 2026-05-13
An Extension Study to Learn About the Long-Term Safety of Fazirsiran and if Fazirsiran Can Help People With Alpha-1 Antitrypsin Liver Disease
Active, not recruitingNCT05899673
Start: 2023-08-08End: 2033-05-02Updated: 2025-10-14
Study to Learn About the Safety of Fazirsiran and if it Can Help People With Alpha-1 Antitrypsin Liver Disease With Mild Liver Scarring (Fibrosis)
RecruitingNCT06165341
Start: 2024-03-01End: 2028-08-26Target: 50Updated: 2026-03-05